Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Analysis, Inspection and Laboratory
LeftNav
Assisted/Independent Living
LeftNav
Clinical and Nursing Equipment
LeftNav
Design and Manufacture of Medical Equipment
LeftNav
Diagnostics Equipment, Monitoring and Test
LeftNav
Education, Training and Professional Services
LeftNav
Health Education and Patient Management
LeftNav
Health Estates Management
LeftNav
Healthcare Support and Information Services
LeftNav
Hygiene and Infection Control
LeftNav
IT and Communications in Healthcare
LeftNav
Materials
LeftNav
Medical Device Technology
LeftNav
Research and Development
LeftNav
Safety and Security
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Health Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
News

University of Virginia and NIDDK select Illumina to process samples for Type 1 Diabetes genetics research

Illumina : 15 October, 2007  (New Product)
Illumina is to process more than 6,500 samples for researchers of the Type 1 Diabetes Genetics Consortium (T1DGC) via its FastTrack Genotyping Services.
With financial support from the NIDDK, the T1DGC will attempt to identify genes that influence an individual's risk for developing type 1 diabetes. Principal investigator Stephen Rich, PhD, from the University of Virginia and chair of the T1DGC Steering Committee has chosen to use Illumina's recently launched HumanHap550-Duo BeadChip for the study.

'Illumina's technology meets the University of Virginia's needs in terms of data quality, call rates, and genomic coverage, and we think that provides us with the most potential for discovering variants linked to complex disease, like type 1 diabetes,' said Dr Stephen Rich, director, Center for Public Health Genomics at the University of Virginia. 'The ultimate goal of this project is gene identification. Once these genes have been identified, researchers can then use this information to develop better approaches to detecting, treating, and preventing the disease.'

According to Beena Akolkar, PhD, programme director, Immunopathogenesis and Genetics of Type 1 Diabetes at the NIDDK, 'The tools and technologies now available to conduct genome-wide association studies are very powerful and have revolutionised the genetics field, leading to an explosion of gene identification in various complex diseases. We look forward to making significant progress in finding all the genes that contribute to susceptibility in type 1 diabetes.'

'One of the strengths of our FastTrack Genotyping Services is our ability to collaborate with customers through every step of their project - from SNP selection through study completion. We believe that this approach helps our customers achieve their scientific goals as rapidly as possible,' said Marc Laurent, director of commercial services. 'NIDDK's contract with Illumina reflects the confidence and trust their scientists are placing in the quality of our technology and support for genotyping services.'

To date, Illumina's FastTrack Genotyping Services group has processed more than 300,000 samples and generated more than 18 billion genotypes, helping researchers around the world to identify genes linked to a number of complex diseases, including psychological disorders, asthma, and cancer.


Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 ProHealthServiceZone.com
Netgains Logo